Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erlotinib + Pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of erlotinib and pembrolizumab is a therapeutic approach that combines two distinct drugs with different mechanisms of action for the treatment of non-small cell lung cancer (NSCLC). Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that works by blocking the EGFR, a protein on cells that encourages cancer cell growth. It inhibits the intracellular phosphorylation of tyrosine kinase associated with EGFR. Pembrolizumab is a monoclonal antibody that binds to the programmed death-1 (PD-1) receptor to block interaction with its ligands, PD-L1 and PD-L2. This binding activates T-cell–mediated immune responses against tumor cells.
- Brand names
- KeytrudaTarceva
- Other names
- pembrolizumaberlotinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on Erlotinib + Pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Erlotinib + Pembrolizumab.